Platelet refractoriness can represent a significant clinical problem that complicates the
provision of platelet transfusions, is associated with adverse clinical outcomes and …

Most of the genes in the major histocompatibility complex (MHC) region express high
polymorphism that is fundamental for their function. The most important function of human …

Despite significant advancements in the production of platelet products, storage, and
transfusion, transfusion refractoriness remains a significant clinical problem, affecting up to …

New transplant approaches are urgently needed for patients with refractory severe aplastic
anemia (SAA) who lack a matched sibling or unrelated donor (UD) or who have failed UD or …

Platelet (PLT) transfusion is indispensable to maintain homeostasis in thrombocytopenic
patients. However, PLT transfusion refractoriness is a common life-threatening condition …

Approximately 20% of patients receiving multiple platelet transfusions develop platelet
alloantibodies, which can be directed against human leukocyte antigens (HLA) and, to a …

Platelet transfusion is routinely used for treating bleeding complications in patients with
hematologic or oncologic clotting disorders, chemo/radiotherapy-induced …

Refractory aplastic anemia (AA) is defined as a lack of response to first-line
immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporin and is …

Over the past 30 years, it has been demonstrated that removal of white blood cells from
blood components is effective in preventing some adverse reactions such as febrile non …

Platelet concentrates account for near 10% of all labile blood components but are
responsible for more than 25% of the reported adverse events. Besides factors related to …